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We thank Dr Berrutti and Dr Leone who in their letter1 , inspired from an updated review2 opened a 
crucial issue regarding the optimal treatment, in the year 2017, of Helicobacter pylori (H. pylori) 
infection in Piedmont, Northern Italy. The recent Maastricht V/Florence Consensus Report of the 
European Helicobacter and Microbiota Study Group has recommended a threshold of 15% to define 
Countries with low and high clarithromycin-resistance rates.3 In Countries with high 
clarithromycin-resistance rates, the bismuth-containing quadruple therapy (with proton pump 
inhibitor [PPI], metronidazole and tetracycline) is the first recommended choice of treatment.3   
   In Piedmont, studies conducted in the last 5 years have shown that clarithromycin-based 
treatments achieved an eradication rate of about 70%.4-6  Treatments based on other macrolides did 
not obtain better results.7 Nevertheless, as reported by Dr Berrutti and Dr Leone, alternative 
treatments did not obtain better outcomes.8 Considering the issue of bacterial resistance at a 
microbiological level, we have participated to a multicentric European study revealing that, in Italy, 
the primary rate of H. pylori clarithromycin resistance was 26.7%.9 In Piedmont, the results were 
not different. Hence, all these data suggested that in this region, clarithromycin-based treatments 
should not be routinely prescribed. Less critical is the situation regarding metronidazole, because in 
contrast to clarithromycin and levofloxacin resistance, the impact of metronidazole resistance on H. 
pylori eradication is limited and can be overcome by increasing the length of treatment or by 
prescription of bismuth-containing quadruple therapy including metronidazole.2 
In conclusion, presently, in Piedmont the first-line treatment for H. pylori infection should be the 
bismuth-containing quadruple therapy. 
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